The increase in price target by Goldman Sachs suggests a more optimistic valuation of Autolus Therapeutics, which could lead to increased investor interest and a potential short-term rise in the stock price. The Neutral rating indicates that Goldman Sachs does not see significant overperformance or underperformance relative to the market or sector.